J Radiat Oncol (2017) 6:279–286 DOI 10.1007/s13566-017-0313-8 ORIGINAL RESEARCH Clinical outcomes following stereotactic body radiation therapy (SBRT) for non-resectable pancreatic adenocarcinoma 1 1 1,2 Raj Singh & Hayden Ansinelli & Sanjeev Sharma Received: 4 April 2017 /Accepted: 3 May 2017 /Published online: 25 May 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract associated with an increased risk of toxicity incidence Objectives The purpose of this study was to report on (5/9 patients vs. 3/51 patients; p =0.001). progression-free survival (PFS), overall survival (OS), and Conclusion SBRT was well-tolerated by PCa patients with related toxicities following stereotactic body radiation therapy fractionated SBRT trending towards superior PFS and less (SBRT) for non-resectable pancreatic cancer (PCa). toxicity as compared to single-fraction SBRT. Methods The RSSearch® Patient Registry was screened for . . PCa patients treated with SBRT. The relationship between Keywords Pancreatic adenocarcinoma Radiotherapy PFS, OS, and potential prognostic factors were evaluated SBRT Registry using the Kaplan-Meier method and continuous log-rank anal- ysis, and the correlation between treatment planning and tox- icity incidence was examined by logistic regression. Introduction Results Sixty patients met inclusion criteria. Twenty-three pa- tients (38.33%) had received adjuvant gemcitabine. Following Pancreatic cancer (PCa) is a major contributor to cancer-related SBRT,
Journal of Radiation Oncology – Springer Journals
Published: May 25, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera